Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: a report of three cases

• 영문명: Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: a report of three cases
• 발행기관: 대한구강악안면외과학회
• 저자명: Soo Young Choi Dami Yoon Kang-Min Kim Sun-Jong Kim Heon-Young Kim Jin-Woo Kim Jung-Hyun Park
• 간행물 정보: 『대한구강악안면외과학회지』제50권 제2호, 103~109쪽, 전체 7쪽
• 주제분류: 의약학 > 내과학
• 파일형태: PDF
• 발행일자: 2024.04.30

영문 초록

Teriparatide has been effective in treating people diagnosed with medication-related osteonecrosis of the jaw (MRONJ). However, its efficacy is not well established to be accepted as a standard of care. The objective of this paper was to investigate the efficacy of recombinant human parathyroid hormone for the treatment of MRONJ. We report three cases of MRONJ patients with osteoporosis as the primary disease who were treated with a teriparatide agent along with other adjunctive measures. Each patient was administered a teriparatide injection subcutaneously for 16 weeks, 36 weeks, or 60 weeks. Surgical intervention including partial resection, sequestrectomy, decortication, and saucerization took place during the teriparatide administration. Complete lesion resolution was identified clinically and radiographically in all three patients. In patients diagnosed with MRONJ, teriparatide therapy is an efficacious and safe therapeutic option to improve healing of bone lesions. These findings demonstrate that teriparatide in combination with another therapy, especially bone morphogenetic protein, platelet-rich fibrin, or antibiotic therapy, can be an effective protocol for MRONJ.

목차

I. Introduction

II. Cases Report

III. Discussion

키워드

Teriparatide Human parathyroid hormone (1-34) Forteo Bisphosphonate-associated osteonecrosis of the jaw Osteoporosis